Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (356)	4/9/2002 4:27:26 AM
From: Icebrg	Read Replies (1) \| Respond to of 1022

From Abbott's news release this morning: ABBOTT PARK, Ill., April 9 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT - news) today announced that it has simultaneously submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Agency for the Evaluation of Medicinal Products (EMEA) seeking approval to market D2E7 (adalimumab, ay-da-lim-yoo-mab) for rheumatoid arthritis (RA). D2E7 is the first fully human monoclonal antibody to be developed. What is the origin of this mAb? As they are now filing for approval they must have had the mAb under development for quite some time. But I have not seen Abgenix or Medarex claiming responsibility for D2E7. So Abbott should have had another mAb-source. How did they do it? Ice